Redx Pharma Receives MHRA’s Positive Response for Restarting its P-I/IIa RXC004 study

 Redx Pharma Receives MHRA’s Positive Response for Restarting its P-I/IIa RXC004 study

Redx Pharma Receives MHRA’s Positive Response for Restarting its P-I/IIa RXC004 study

Shots:
  • Redx is working on study including lower starting dose and enhanced safety monitoring, assessing safety and tolerability of drug in patients with advance malignancies
  • Redx claims that RXC004 a porcupine inhibitor belong to WNT signalling pathway, seems to be an attractive combination companion for immune-oncology agents
  •  Redx will finalize the suspended protocol for dosing of patients in H1’19 

Click here to read full press release/ article | Ref: Redx Pharma | Image:  Apconix

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post